Palma de Mallorca

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Amyloidosis4 trials
• Heart failure2 trials
• Metastatic breast cancer2 trials
• Asthma1 trial
• Chronic lymphocytic leukaemia1 trial
• COPD1 trial
• Mantle cell lymphoma1 trial
• Ovarian cancer1 trial

Phase

• Phase 35 trials
• Phase 21 trial
• Phase 41 trial

Status

• Completed4 trials
• Not yet recruiting4 trials
• Active, not recruiting2 trials
• Recruiting1 trial
• Terminated1 trial

Lead sponsor

• AstraZeneca10 trials
• Alexion Pharmaceuticals, Inc.2 trials

Running trials

• Not yet recruiting

  An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

  NCT07789483· Phase 3· Alexion Pharmaceuticals, Inc.· Source

  Contact: Alexion Pharmaceuticals, Inc., Sponsor

• Recruiting

  Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer

  NCT07851025· Phase 3· AstraZeneca· Source

• Recruiting

  Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM

  NCT07690436· AstraZeneca· Source

• Recruiting

  A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

  NCT07647328· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain

  NCT07029737· Phase 2· AstraZeneca· Source

• Active, not recruiting

  Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

  NCT06183931· Phase 3· Alexion Pharmaceuticals, Inc.· Source

• Recruiting

  PICAROS - Acalabrutinib RWE on 1L CLL in Spain

  NCT05999877· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis2 recruiting
• Heart failure1 recruiting
• Mantle cell lymphoma1 recruiting
• Metastatic breast cancer1 recruiting
• Ovarian cancer1 recruiting

Closed trials

• Completed

  Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

  NCT06750289· Phase 3· AstraZeneca· Source

• Completed

  Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain.

  NCT06321731· AstraZeneca· Source

• Recruiting

  OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

  NCT06355934· AstraZeneca· Source

• Terminated

  An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

  NCT05592483· AstraZeneca· Source

• Completed

  Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone

  NCT04676646· Phase 4· AstraZeneca· Source